Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury

Cisplatin is a commonly used chemotherapeutic for the treatment of many solid organ cancers; however, its effectiveness is limited by the development of acute kidney injury (AKI) in 30% of patients. AKI is driven by proximal tubule cell death, leading to rapid decline in renal function. It has previ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sears, Sophia M., Dupre, Tess V., Shah, Parag P., Davis, Deanna L., Doll, Mark A., Sharp, Cierra N., Vega, Alexis A., Megyesi, Judit, Beverly, Levi J., Snider, Ashley J., Obeid, Lina M., Hannun, Yusuf A., Siskind, Leah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953688/
https://www.ncbi.nlm.nih.gov/pubmed/35151662
http://dx.doi.org/10.1016/j.jlr.2022.100179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953688/
https://www.ncbi.nlm.nih.gov/pubmed/35151662
http://dx.doi.org/10.1016/j.jlr.2022.100179

Ejemplares similares